CORRECTION – AVEO Oncology Announces Appointment of Chief Medical Officer and Formation of Scientific Advisory Committee
28 mars 2024 15h22 HE
|
AVEO Pharmaceuticals, Inc.
– Industry veteran brings extensive clinical development experience to AVEO Oncology leadership team as Chief Medical Officer – – Formation of a Scientific Advisory Committee from world-renowned...
AVEO Oncology Announces Appointment of Chief Medical Officer and Formation of Scientific Advisory Committee
25 mars 2024 08h10 HE
|
AVEO Pharmaceuticals, Inc.
– Industry veteran brings extensive clinical development experience to AVEO Oncology leadership team as Chief Medical Officer – – Formation of a Scientific Advisory Committee from...
AVEO Oncology Announces Publication of Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 Trial in The Oncologist
06 févr. 2024 08h10 HE
|
AVEO Pharmaceuticals, Inc.
AVEO Oncology Announces Publication of Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib
FDA Grants Fast Track designation to IVS-3001, a CAR-T Cell Therapy in the Treatment of Renal Cell Carcinoma
31 juil. 2023 06h00 HE
|
Invectys, Inc.
Houston, TX, USA, July 31, 2023 (GLOBE NEWSWIRE) -- Invectys, Inc., a clinical-stage immuno-oncology company focused on developing novel therapies for advanced cancers, is pleased to announce the...
Vaccentis Appoints Dr. Ingrid Rauter as Chief Medical Officer and Head of Research & Development
03 mai 2023 03h00 HE
|
Vaccentis AG
Zurich, Switzerland, May 3, 2023 - Vaccentis AG, a clinical-stage Swiss biopharmaceutical company developing patient-individualized medicines, today announced the appointment of the experienced life...
Vaccentis strengthens leadership with appointment of Mario Stark as Chief Sales and Marketing Officer
08 sept. 2022 02h00 HE
|
Vaccentis AG
Life science executive with experience in ophthalmology, branding, marketing and financingWill lead sales and marketing of medicines for dry eye and autoimmune diseases Zurich, Switzerland,...
Vaccentis stärkt Management durch Berufung von Martin Munte zum CEO
12 juil. 2022 02h00 HE
|
Vaccentis AG
Pharmamanager mit langjährige Führungserfahrung bei Amgen, AstraZeneca und RocheWeitere Verstärkung des Managements nach Ernennung dreier neuer Mitglieder im Verwaltungsrat Zurich, Schweiz, 12....
Vaccentis appoints Martin Munte as CEO and strengthens Board
12 juil. 2022 02h00 HE
|
Vaccentis AG
Martin Munte has extensive leadership experience at Amgen, AstraZeneca and RocheStrengthening management after appointment of three new Board members Zurich, Switzerland, July 12, 2022 -...
Allarity Therapeutics Submits New Drug Application (NDA) to the U.S. FDA for Dovitinib for Third-Line Treatment of Renal Cell Carcinoma (RCC)
22 déc. 2021 08h00 HE
|
Allarity Therapeutics, Inc.
Marks Allarity’s first regulatory application for marketing approval for one of its prioritized oncology pipeline programs NDA is supported by Allarity’s previously-filed pre-market approval (PMA)...
Cerulean Reports Third-Quarter 2014 Corporate Highlights and Financial Results
13 nov. 2014 16h06 HE
|
Daré Bioscience, Inc.
CAMBRIDGE, Mass., Nov. 13, 2014 (GLOBE NEWSWIRE) -- Cerulean Pharma Inc. (Nasdaq:CERU), a leader in Dynamic Tumor Targeting™, today provided an update on corporate activities during the quarter...